SpringWorks Therapeutics Inc (NASDAQ: SWTX)’s stock price has gone decline by -2.99 in comparison to its previous close of 57.43, however, the company has experienced a 3.17% increase in its stock price over the last five trading days. globenewswire.com reported 2025-02-17 that LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc. for GOMEKLI (mirdametinib). The Food & Drug Administration approved GOMEKLI for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1
Is It Worth Investing in SpringWorks Therapeutics Inc (NASDAQ: SWTX) Right Now?
SWTX has 36-month beta value of 0.85. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SWTX is 62.04M, and currently, short sellers hold a 23.22% ratio of that float. The average trading volume of SWTX on February 18, 2025 was 1.85M shares.
SWTX’s Market Performance
The stock of SpringWorks Therapeutics Inc (SWTX) has seen a 3.17% increase in the past week, with a 56.53% rise in the past month, and a 60.50% gain in the past quarter. The volatility ratio for the week is 15.15%, and the volatility levels for the past 30 days are at 8.59% for SWTX. The simple moving average for the past 20 days is 29.33% for SWTX’s stock, with a 47.03% simple moving average for the past 200 days.
Analysts’ Opinion of SWTX
Many brokerage firms have already submitted their reports for SWTX stocks, with Evercore ISI repeating the rating for SWTX by listing it as a “Outperform.” The predicted price for SWTX in the upcoming period, according to Evercore ISI is $60 based on the research report published on November 20, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see SWTX reach a price target of $75. The rating they have provided for SWTX stocks is “Buy” according to the report published on February 05th, 2024.
BofA Securities gave a rating of “Buy” to SWTX, setting the target price at $45 in the report published on December 01st of the previous year.
SWTX Trading at 39.23% from the 50-Day Moving Average
After a stumble in the market that brought SWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.15% of loss for the given period.
Volatility was left at 8.59%, however, over the last 30 days, the volatility rate increased by 15.15%, as shares surge +60.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.90% upper at present.
During the last 5 trading sessions, SWTX rose by +3.15%, which changed the moving average for the period of 200-days by +19.30% in comparison to the 20-day moving average, which settled at $43.08. In addition, SpringWorks Therapeutics Inc saw 54.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SWTX starting from DANIEL LYNCH, who proposed sale 48,000 shares at the price of $58.59 back on Feb 14 ’25. After this action, DANIEL LYNCH now owns shares of SpringWorks Therapeutics Inc, valued at $2,812,320 using the latest closing price.
Pichl Daniel, the Chief People Officer of SpringWorks Therapeutics Inc, sale 29,750 shares at $54.36 during a trade that took place back on Feb 10 ’25, which means that Pichl Daniel is holding 50,762 shares at $1,617,329 based on the most recent closing price.
Stock Fundamentals for SWTX
Current profitability levels for the company are sitting at:
- -2.18 for the present operating margin
- 0.94 for the gross margin
The net margin for SpringWorks Therapeutics Inc stands at -2.03. The total capital return value is set at -0.55. Equity return is now at value -59.33, with -51.12 for asset returns.
Based on SpringWorks Therapeutics Inc (SWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -30.22. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -69.0.
Currently, EBITDA for the company is -341.35 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 30.06. The receivables turnover for the company is 4.11for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.16.
Conclusion
To put it simply, SpringWorks Therapeutics Inc (SWTX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
